These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 21348806

  • 1. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC, Conner C, Hammer M.
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [Abstract] [Full Text] [Related]

  • 2. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 3. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC, Conner C, Hammer M.
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 5. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.
    J Med Econ; 2012 Jun; 15 Suppl 2():1-5. PubMed ID: 22853443
    [Abstract] [Full Text] [Related]

  • 6. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.
    Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.
    Cardiovasc Diabetol; 2009 Feb 26; 8():12. PubMed ID: 19245711
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep 26; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 9. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
    Davies MJ, Chubb BD, Smith IC, Valentine WJ.
    Diabet Med; 2012 Mar 26; 29(3):313-20. PubMed ID: 21883438
    [Abstract] [Full Text] [Related]

  • 10. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Mar 26; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D.
    Clin Ther; 2004 Nov 26; 26(11):1783-90. PubMed ID: 15639690
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH.
    J Med Econ; 2012 Nov 26; 15(6):1039-50. PubMed ID: 22533526
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Tunis SL, Minshall ME, St Charles M, Pandya BJ, Baran RW.
    Curr Med Res Opin; 2008 Nov 26; 24(11):3085-96. PubMed ID: 18826750
    [Abstract] [Full Text] [Related]

  • 16. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus.
    Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.
    Pharmacotherapy; 2009 Nov 26; 29(11):1280-8. PubMed ID: 19873688
    [Abstract] [Full Text] [Related]

  • 17. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
    Diabetes Res Clin Pract; 2012 Aug 26; 97(2):258-66. PubMed ID: 22446097
    [Abstract] [Full Text] [Related]

  • 18. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D.
    Prim Care Diabetes; 2010 Jul 26; 4(2):113-7. PubMed ID: 20444662
    [Abstract] [Full Text] [Related]

  • 19. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Jul 26; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 20. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL, Minshall ME.
    Curr Med Res Opin; 2010 Jan 26; 26(1):151-62. PubMed ID: 19919376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.